Inogen Inc (INGN) — Titan Protect Analysis

INGN

Inogen Inc

Healthcare · ·

$6.41

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$164M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-23.33

Based on estimated future earnings — lower means cheaper

Rev Growth

+3.4%

Year-over-year revenue change

Profit Margin

-7.1%

How much profit the company keeps from each dollar of revenue

ROE

-13.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.00

+87% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Inogen Inc

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen

https://www.provider.inogen.com

Country: United States Employees: 753 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.038

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0206

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.220

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-12.5%

Historical annualised return based on price data

Max Drawdown

-56.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.65

Significantly more volatile than the market

52W High

$9.13

30% below the year high

52W Low

$5.34

20% above the year low

Avg Volume

316,331

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.91

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

9.26

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

44.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-9.9%

Profit from core operations before interest and tax

Free Cash Flow

$-2,406,250

Negative — the business is spending more than it generates

Revenue (TTM)

$351M

Total revenue over the last 12 months

Net Income

$-24,897,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$14.00

Target Median

$12.00

Target Low

$12.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go